IPSOGEN, a cancer profiler that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, has announced that it has successfully carried out a E2.5 million capital increase.
The raising of funds was done within the framework of the law that reduces wealth tax (TEPA act), said the company. The funding was done via reserved capital increase, in accordance with the decisions approved during the company’s Annual General Meeting on May 20 2009. The capital increase concerned a total of 367647 shares issued at E6.80 per share.
Stanislas PIOT, CFO of IPSOGEN, said: “This raising of a further 2.5 million euros was essentially carried out with new investors. Done at a similar price to the one at the time of the IPO in June 2008, it reflects investors’ confidence in our strategy and in our share price’s upside potential.”